SEC 13F Intelligence

Lion Point Capital, LP / CTIC1USD

Lion Point Capital, LP’s Cti Biopharma Corp Position

Does Lion Point Capital, LP own Cti Biopharma Corp (CTIC1USD)? Not currently — the last reported position was 601.6K shares worth $3M in Q1 2023; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$3M
Q1 2023
Shares
601.6K
% of Portfolio
+1.04%
Quarters Held
6
position exited

Position History CTIC1USD

Reported value by quarter
Q4 ’21: $3MQ4 ’21Q1 ’22: $26MQ1 ’22Q2 ’22: $14MQ2 ’22Q3 ’22: $12MQ3 ’22Q4 ’22: $11MQ4 ’22Q1 ’23: $3MQ1 ’23filingsflow.com
QuarterSharesValue% of Portfolio
Q1 2023601.6K$3M+1.04%
Q4 20223.70M$11M+1.51%
Q3 20224.39M$12M+2.57%
Q2 20225.49M$14M+1.65%
Q1 20225.49M$26M+5.95%
Q4 20211.22M$3M+0.81%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Lion Point Capital, LP’s full portfolio or all institutional holders of CTIC1USD.